Clinical Trial Update: Dronabinol for Agitation in Dementia Crossover Trial [Phase 2]

View source ↗

Summary

A Phase 2 crossover trial evaluating dronabinol for agitation in patients with dementia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia

Drugs mentioned

• Dronabinol (dronabinol)

Snippet

Sponsor: Ralph H. Johnson VA Medical Center | Conditions: Dementia Moderate, Dementia Severe | Phase 2 | Status: WITHDRAWN